Immuno-inflammatory mechanisms in cardio-oncology: new hopes for immunotargeted therapies DOI Creative Commons

Meiqi Miao,

Xinxin Liu, Han Zhang

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: March 13, 2025

Cardio-oncology is an emerging interdisciplinary field concerned with cancer treatment-related cardiovascular toxicities (CTR-CVT) and concomitant diseases (CVD) in patients cancer. Inflammation immune system dysregulation are common features of tumors disease (CVD). In addition to the mutual exacerbating effect through inflammation, tumor treatments, including immunotherapy, chemotherapy, radiation therapy, targeted may induce inflammatory reactions leading damage. Cancer immunotherapy currently a new method treatment. Immunotherapeutic agents, such as checkpoint inhibitors (ICIs), chimeric antigen receptor T cell (CAR-T), mRNA vaccines, etc., can anti-tumor effects by enhancing host response eliminate cells. They have achieved remarkable therapeutic efficacy clinical settings but lead many immune-related adverse events (irAEs), especially CTR-CVT. Establishing specific evaluation, diagnostic, monitoring criteria (e.g., biomarkers) for both anti-inflammatory therapy-related toxicity vital guide practice. This article explores role inflammation cardiology, unravels underlying mechanisms, provides improved methods treating CTR-CVT cardio-oncology.

Language: Английский

To explore the influencing factors of clinical failure of anti-tumor necrosis factor-α (TNF-α) therapy in sepsis DOI
Yonghong Zhou, Zaixin Yu, Yiming Lu

et al.

Life Sciences, Journal Year: 2025, Volume and Issue: 369, P. 123556 - 123556

Published: March 9, 2025

Language: Английский

Citations

0
Immuno-inflammatory mechanisms in cardio-oncology: new hopes for immunotargeted therapies DOI Creative Commons

Meiqi Miao,

Xinxin Liu, Han Zhang

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: March 13, 2025

Cardio-oncology is an emerging interdisciplinary field concerned with cancer treatment-related cardiovascular toxicities (CTR-CVT) and concomitant diseases (CVD) in patients cancer. Inflammation immune system dysregulation are common features of tumors disease (CVD). In addition to the mutual exacerbating effect through inflammation, tumor treatments, including immunotherapy, chemotherapy, radiation therapy, targeted may induce inflammatory reactions leading damage. Cancer immunotherapy currently a new method treatment. Immunotherapeutic agents, such as checkpoint inhibitors (ICIs), chimeric antigen receptor T cell (CAR-T), mRNA vaccines, etc., can anti-tumor effects by enhancing host response eliminate cells. They have achieved remarkable therapeutic efficacy clinical settings but lead many immune-related adverse events (irAEs), especially CTR-CVT. Establishing specific evaluation, diagnostic, monitoring criteria (e.g., biomarkers) for both anti-inflammatory therapy-related toxicity vital guide practice. This article explores role inflammation cardiology, unravels underlying mechanisms, provides improved methods treating CTR-CVT cardio-oncology.

Language: Английский

Citations

0